New therapeutic strategies under development to halt the progression of renal failure

Expert Opinion on Investigational Drugs

Volumn 23, Issue 5, 2014, Pages 693-709

  Cernaro, Valeria ^a   Trifirò, Gianluca ^a   Lorenzano, Giuseppina ^a   Lucisano, Silvia ^a   Buemi, Michele ^a   Santoro, Domenico ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Chronic kidney disease; Glomerulonephritis; Progression; Therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIHYPERTENSIVE AGENT; ATRASENTAN; BENAZEPRIL; BICARBONATE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN A RECEPTOR ANTAGONIST; EVEROLIMUS; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEDIPINE; PARICALCITOL; PHOSPHODIESTERASE V INHIBITOR; SITAXSENTAN; VALSARTAN; VITAMIN D DERIVATIVE; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; DIABETIC PATIENT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; FIBROSING ALVEOLITIS; HUMAN; INFLAMMATION; KIDNEY POLYCYSTIC DISEASE; LIFESTYLE MODIFICATION; LOW CALORY DIET; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLIC ACIDOSIS; MULTICENTER STUDY (TOPIC); OBESITY; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PODOCYTE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT CHANGE; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE COURSE; RENAL INSUFFICIENCY; STEM CELL TRANSPLANTATION; TRENDS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; RENAL INSUFFICIENCY; STEM CELL TRANSPLANTATION; VITAMIN D;

EID: 84898404702     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.899352     Document Type: Review

References (80)

1. Baltatzi M, Savopoulos Ch, Hatzitolios A. Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results. Hippokratia 2011;15(Suppl 1):27-32
2. Upadhyay A. Statins in chronic kidney disease: What do meta-Analyses tell us? Clin Exp Nephrol 2013. [Epub ahead of print]
3. Perico N, Zoja C, Corna D, et al. V1/V2 vasopressin receptor antagonism potentiates the renoprotection of renin-Angiotensin system inhibition in rats with renal mass reduction. Kidney Int 2009;76(9):960-7
4. Cernaro V, Lacquaniti A, Donato V, et al. Fibrosis, regeneration and cancer: What is the link? Nephrol Dial Transplant 2012;27(1):21-7
5. Available from: Http://clinicaltrials.gov/ct2/home 6. Ruilope LM. Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr Med Res Opin 2008;24(5):1285-93
6. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med 1993;329:977-86
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329(20):1456-62
8. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-64
9. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361(1):40-51
10. Proesmans W, Van Dyck M. Enalapril in children with alport syndrome. Pediatr Nephrol 2004;19(3):271-5
11. Gross O, Licht C, Anders HJ, et al. Early angiotensin-converting enzyme inhibition in alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012;81(5):494-501
12. Wolk R, Smith WB, Neutel JM, et al. Blood pressure lowering effects of a new long-Acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. Hypertension 2009;53(6):1091-7
13. Eid H, de Bold ML, Chen JH, de Bold AJ. Epicardial mesothelial cells synthesize and release endothelin. J Cardiovasc Pharmacol 1994;24(5):715-20
14. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997;29(1):2-26
15. Kohan DE. Role of collecting duct endothelin in control of renal function and blood pressure. Am J Physiol Regul Integr Comp Physiol 2013;305(7):R659-68
16. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006;17(4):943-55
17. Dhaun N, MacIntyre IM, Kerr D, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011;57(4):772-9
18. Nakov R, Pfarr E, Eberle S, HEAT Investigators. Darusentan: An effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002;15(7 Pt 1):583-9
19. Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-Angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011;22(4):763-72
20. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. Circulation 2004;109(9):1186-93
21. Dhaun N, Macintyre IM, Melville V, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension 2009;54(1):113-19
22. Morigi M, Buelli S, Angioletti S, et al. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: Implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005;166:1309-20
23. Chen JF, Ni HF, Pan MM, et al. Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats. Am J Physiol Renal Physiol 2013;304(6):F676-85
24. Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007;2(5):906-13
25. Braman V, Graham P, Cheng C, et al. A randomized phase I evaluation of CTP-499, a novel deuterium-containing drug candidate for diabetic nephropathy. Clinical Pharm in Drug Dev 2013;2:53-66
26. Streetly MJ, Maharaj L, Joel S, et al. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood 2010;115(19):3939-48
27. O'Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2011;9(1):22-31
28. O'Seaghdha CM, Hwang SJ, Ho JE, et al. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 2013;24(9):1470-7
29. Lee EA, Seo JY, Jiang Z, et al. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int 2005;67(5):1762-71
30. Sung CC, Hsu YC, Chen CC, et al. Oxidative stress and nucleic acid oxidation in patients with chronic kidney disease. Oxid Med Cell Longev 2013;2013:301982
31. Reisman SA, Chertow GM, Hebbar S, et al. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol 2012;23(10):1663-73
32. Pergola PE, Raskin P, Toto RD, et al. BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365(4):327-36
33. de Zeeuw D, Akizawa T, Audhya P, et al. BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013;369(26):2492-503
34. Santoro D, Caccamo D, Gagliostro G, et al. Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients. J Nephrol 2013;26(4):636-44
35. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009;75(1):88-95
36. Santoro D, Gitto L, Ferraro A, et al. Vitamin D status and mortality risk in patients with chronic kidney disease. Ren Fail 2011;33(2):184-91
37. Fernandez-Juarez G, Luño J, Barrio V, et al.; PRONEDI Study Group. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-Angiotensin system. Clin J Am Soc Nephrol 2013;8(11):1870-6
38. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev 2008;29(6):726-76
39. Jones G. Expanding role for vitamin D in chronic kidney disease: Importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial 2007;20(4):316-24
40. Min B. Effects of vitamin D on blood pressure and endothelial function. Korean J Physiol Pharmacol 2013;17(5):385-92
41. Lucisano S, Buemi M, Passantino A, et al. New insights on the role of vitamin d in the progression of renal damage. Kidney Blood Press Res 2013;37(6):667-78
42. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-Angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74(11):1394-402
43. Molinari C, Uberti F, Grossini E, et al. 1a,25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells. Cell Physiol Biochem 2011;27(6):661-8
44. Larsen T, Mose FH, Bech JN, Pedersen EB. Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: A randomized placebo-controlled trial. BMC Nephrol 2013;14(1):163
45. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 2010;376(9752):1543-51
46. Feneis JF, Arora RR. Role of vitamin D in blood pressure homeostasis. Am J Ther 2010;17(6):e221-9
47. Perez-Go'mez MV, Ortiz-Arduan A, Lorenzo-Sellares V. Vitamin D and proteinuria: A critical review of molecular bases and clinical experience. Nefrologia 2013;33(5):716-26
48. Kovesdy CP. Metabolic acidosis and kidney disease: Does bicarbonate therapy slow the progression of CKD? Nephrol Dial Transplant 2012;27(8):3056-62
49. Kraut JA, Kurtz I. Metabolic acidosis of CKD: Diagnosis, clinical characteristics, and treatment. Am J Kidney Dis 2005;45(6):978-93
50. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009;20(9):2075-84
51. Mahajan A, Simoni J, Sheather SJ, et al. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010;78(3):303-9
52. Abramowitz MK, Melamed ML, Bauer C, et al. Effects of oral sodium bicarbonate in patients with CKD. Clin J Am Soc Nephrol 2013;8(5):714-20
53. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant 2009;24(4):1232-7
54. Buemi M, Campo S, Donato V, et al. A new therapy for kidney injury: Regeneration. Eur Rev Med Pharmacol Sci 2011;15(2):111-21
55. Herrera M, Mirotsou M. Stem cells: Potential and challenges for kidney repair. Am J Physiol Renal Physiol 2014;306(1):F12-23
56. Sciancalepore AG, Sallustio F, Girardo S, et al. A bioartificial renal tubule device embedding human renal stem/progenitor cells. PLoS One 2014;9(1):e87496
57. Ruan GP, Xu F, Li ZA, et al. Induced autologous stem cell transplantation for treatment of rabbit renal interstitial fibrosis. PLoS One 2013;8(12):e83507
58. Yokote S, Yamanaka S, Yokoo T. De novo kidney regeneration with stem cells. J Biomed Biotechnol 2012;2012:453519
59. Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: A systematic review. Nephrol Dial Transplant 2013;28(Suppl 4):iv82-98
60. Jezior D, Krajewska M, Madziarska K, et al. Weight reduction in renal transplant recipients program: The first successes. Transplant Proc 2007;39(9):2769-71
61. Rettkowski O, Wienke A, Hamza A, et al. Low body mass index in kidney transplant recipients: Risk or advantage for long-Term graft functioñ Transplant Proc 2007;39(5):1416-20
62. Torra R. [Treatment of autosomal dominant polycystic kidney disease]. Med Clin (Barc) 2014;142(2):73-9
63. Wu M, Wahl PR, Le Hir M, et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007;30(4):253-9
64. Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010;363(9):830-40
65. Xue C, Dai B, Mei C. Long-Term treatment with Mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: A meta-Analysis. Nephron Clin Pract 2013;124(1-2):10-16
66. Torres VE, Chapman AB, Devuyst O, et al.; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367(25):2407-18
67. Caroli A, Perico N, Perna A, et al.; ALADIN study group. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebocontrolled, multicentre trial. Lancet 2013;382(9903):1485-95
68. Rastogi A. Sevelamer revisited: Pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis 2013;7(6):322-42
69. Zoccali C, Ruggenenti P, Perna A, et al.; GREIN Study Group. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011;22(10):1923-30
70. Trachtman H, Greenbaum LA, McCarthy ET, et al. Glomerular permeability activity: Prevalence and prognostic value in pediatric patients with idiopathic nephrotic syndrome. Am J Kidney Dis 2004;44(4):604-10
71. Suzuki A, Ito T, Imai E, et al. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol 2003;14(4):981-91
72. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition; a patient level metaanalysis. Ann Intern Med 2003;139:244-52
73. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end stage renal disease. Kidney Int 2003;63:1468-73
74. Zeisberg M, Strutz F, Muller GA. Renal fibrosis: An update Curr Opin Nephrol Hypertens. 2000;10:315-20
75. Schieppati A, Remuzzi G. Proteinuria and its consequences in renal disease. Acta Paediatr 2003;92:9-13
76. de Jong PE, Verhave JC, Pinto-Sietsma SJ, et al. Obesity and target organ damage: The kidney. Int J Obes Relat Metab Disord 2002;26(Suppl 4):S21-4
77. Kambham N, Markowitz GS, Valeri AM. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001;59:1498-509
78. El Nahas AM. Plasticity of kidney cells: Role in kidney remodelling and scarring. Kidney Int 2003;64:1553-63
79. Wang S, Li Y, Zhao J, et al. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transplant 2013;19(4):538-46
80. Villanueva S, Carreño JE, Salazar L, et al. Human mesenchymal stem cells derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure. Clin Sci (Lond) 2013;125(4):199-210